The first Ebola vaccine took roughly 20 years from initial laboratory work to regulatory approval. Scientists at Canada’s National Microbiology Laboratory began developing the vaccine concept in 1999, and it received approval from the European Medicines Agency in November 2019 and the U.S. FDA in December 2019. That said, most of those two decades were marked by slow progress and limited funding. The intense phase of clinical development lasted only about five years, compressed by the urgency of the 2013–2016 West African outbreak.
Early Research in Canada: 1999–2013
The story starts with Heinz Feldmann, a scientist who joined Canada’s National Microbiology Laboratory in Winnipeg in 1999. Feldmann believed that a specific protein on the surface of the Ebola virus was key to how the disease caused such severe illness. Working with colleague Ute Ströher, his team built a vaccine candidate by taking a harmless livestock virus (vesicular stomatitis virus) and swapping one of its surface proteins for the Ebola protein. This taught the immune system to recognize Ebola without any risk of actual infection.
The vaccine showed strong results in animal studies, but for over a decade it sat largely on the shelf. Ebola outbreaks before 2013 were relatively small and confined to remote areas, which meant there was little commercial incentive for pharmaceutical companies to invest in expensive human trials. Funding was scarce, and no one pushed the candidate into large-scale clinical testing. For context, the CDC notes that vaccine development typically takes 10 to 15 years of laboratory research alone. This vaccine’s early phase stretched even longer than that norm.
The 2014 Outbreak Changed Everything
The 2013–2016 Ebola outbreak in West Africa was the largest in history, killing more than 11,000 people and becoming only the third Public Health Emergency of International Concern ever declared at that time. Suddenly, an Ebola vaccine was no longer a low-priority project. Governments, international organizations, and pharmaceutical companies mobilized in an unprecedented joint effort to push the Canadian-origin vaccine candidate through human trials as fast as possible.
Merck acquired the vaccine program and began compressing what would normally be a decade-long clinical development process into a fraction of that time. Multiple trial phases overlapped rather than running sequentially, and regulatory agencies provided accelerated review pathways. The result: just five years elapsed between Merck’s acquisition of the program and full regulatory approval.
A Landmark Trial in Guinea
The pivotal moment came in 2015 with a trial in Guinea that used a clever “ring vaccination” strategy borrowed from the smallpox eradication campaign. When a new Ebola case was identified, researchers vaccinated the ring of people around that case, including family members, neighbors, and contacts. Some rings received the vaccine immediately, while others received it after a three-week delay.
Between April and July 2015, the trial enrolled over 7,600 people across 90 clusters. The results were striking: among people vaccinated immediately, there were zero Ebola cases starting 10 or more days after vaccination. The delayed group had 16 cases. That translated to 100% efficacy in preventing Ebola in vaccinated individuals, a result published in The Lancet that made the case for approval essentially undeniable.
Approval and Rollout: 2019–2020
The vaccine, branded as Ervebo, received conditional marketing authorization from the European Medicines Agency on November 11, 2019, followed by FDA approval in December 2019. It became the first vaccine ever approved specifically for Ebola. A second vaccine regimen from Johnson & Johnson, using a two-dose approach, received European approval in July 2020, giving health authorities an additional tool.
To support access in the countries that need it most, Gavi, the global vaccine alliance, committed $178 million to create an Ebola vaccine stockpile, ensuring low- and middle-income countries could receive the vaccine at no cost.
Why Storage Remains a Challenge
Even after approval, getting Ervebo to the remote communities where Ebola outbreaks typically occur presents real logistical hurdles. The vaccine must be shipped frozen at temperatures between minus 60°C and minus 80°C, requiring specialized ultra-cold freezers. If that kind of storage isn’t available at a vaccination site, thawed doses can be kept in a standard refrigerator (2°C to 8°C) for up to 14 days, or at room temperature for up to four hours. In regions with unreliable electricity and limited cold-chain infrastructure, those constraints make distribution significantly harder than for most routine vaccines.
Why It Took So Long
The 20-year timeline from lab to approval wasn’t because the science was unusually difficult. The vaccine worked well in animals relatively early on. The delay was almost entirely a matter of priorities and funding. Ebola, before 2014, was seen as a disease that affected small numbers of people in remote parts of Central and West Africa. No pharmaceutical company saw a viable market, and public funding for Ebola-specific vaccine research was minimal.
Once a crisis forced the world’s hand, the intensive development phase took about five years, roughly half the 10-to-15-year average for conventional vaccine development. That compression was possible because of massive coordinated investment, overlapping trial phases, and regulatory agencies willing to expedite reviews during a public health emergency. The Ebola vaccine story became a template for how the global health community could accelerate development when the will and resources align, a lesson that resurfaced during the COVID-19 pandemic just months after Ervebo’s approval.